EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes

Adrian Heald iD, Yasitha Lllangasekera, Andreas Matheou, Ram Prakash Narayanan, Stephen White, Hellena Habte-Asres, Abigail Lay, Liliana Shalamanova, William Ollier, Graham A Hitman, Ritwika Mallik, Philip A Kalra und 2 weitere

Diabetic Medicine · 2026

DOI: 10.1111/dme.70318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Adrian Heald und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Insulin-Like Growth Factor II, Insulin-Like Growth Factor I. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic kidney disease is associated with dysregulation of the insulin‐like growth factor (IGF) system. Alterations in IGF bioavailability, driven by IGF binding proteins (IGFBPs), may influence the decline in renal function. However, the longitudinal relationship between baseline IGF‐I, IGF‐II, IGFBPs and progression of kidney dysfunction remains unclear. We evaluated how IGF/IGFBP profile relates to longitudinal changes in urinary albumin/creatinine ratio (ACR) and serum creatinine level in people with type 2 diabetes (T2D).

Methods

Individuals' measurements were performed in 436 individuals with T2D recruited from primary and secondary care (2002–2004), from the Salford and Manchester Integrated Care Record (GMCR), for laboratory and clinical data, as well as date of death. Baseline IGF/IGFBP profile was related to 2 primary outcomes: (i) change in albumin‐to‐creatinine ratio over time (urine ACR trend slope) and (ii) change in serum creatinine over time (creatinine trend slope). Trend slopes were derived for each participant, using repeated measures throughout follow‐up for up to 24 years. Associations between IGF axis proteins and outcomes were evaluated with multivariate regression models. Cox proportional hazards models were constructed to determine mortality risk associated with the IGF system proteins studied.

Results

At baseline, 59.3% of participants were men. Age at baseline was 56.6 ± 9.4 years. Mean follow‐up duration was 17.4 ± 5.2 years. IGF‐II and IGFBP‐3 were strongly correlated (Spearman rho = 0.80), and were therefore not included simultaneously in the multi‐variate linear regression model to avoid co‐linearity. Higher circulating IGFBP‐2 was independently associated with faster rate of ACR progression (normalised beta (Β) = 0.007, p = 0.002), while IGFBP‐1 showed an inverse association ( B = −0.057, p = 0.009). IGF‐II also remained positively associated with ACR trend ( B = 0.005, p = 0.013), whereas IGF‐I showed no association. IGFBP‐1 showed a significant inverse association with creatinine change when adjusted for effects of covariates (unstandardised B = −0.038, p = 0.04). Survival analysis revealed that higher IGFBP‐2 levels were independently associated with higher all‐cause mortality (hazard ratio [HR] per 1 standard deviation increase 1.306, 95% CI 1.151–1.483 p = 0.0001).

Conclusion

This longitudinal study indicated that higher baseline IGF‐II, lower IGFBP‐1 and higher IGFBP‐2 are associated with a greater likelihood of albuminuria progression, independent of standard risk factors; lower IGBFP‐1 also associated with greater increase in serum creatinine. Higher circulating IGFBP‐2 level was also associated with relatively higher mortality. This study demonstrated the relevance of the IGF system to our understanding of renal complications in diabetes and strongly suggests that further exploration of mechanisms underlying these associations is merited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesInsulin-Like Growth Factor IIInsulin-Like Growth Factor IRenal Insufficiency, ChronicInsulin-Like Growth Factor Binding ProteinsHumansMaleFemaleMiddle AgedDisease ProgressionCreatinineAgedAlbuminuriaInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Longitudinal Studies

Stichwörter der Autor:innen

CKDIGFIGFBPalbuminuriamortalityprogressiontype 2 diabetes

Substanzen

Insulin-Like Growth Factor IIInsulin-Like Growth Factor ICreatinineInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding Proteins

Autor:innen und Institutionen

  • University of Manchester, Manchester, UK.
  • Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK.
  • Sheffield Hallam University, Sheffield, UK.
  • Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.
  • Diabetes Centre, St Helens Hospital, St Helens, UK.
  • University of Newcastle, Newcastle, UK.

ORCID-Profile: Adrian Heald, Martin Whyte

Zitieren

APA

Heald, A., Lllangasekera, Y., Matheou, A., Narayanan, R. P., White, S., Habte-Asres, H., Lay, A., Shalamanova, L., Ollier, W., Hitman, G. A., Mallik, R., Kalra, P. A., Whyte, M., & Gibson, J. M. (2026). The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/dme.70318

Vancouver

Heald A, Lllangasekera Y, Matheou A, Narayanan RP, White S, Habte-Asres H, et al. The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes. Diabetic Medicine. 2026. doi:10.1111/dme.70318

BibTeX
@article{Heald2026,
  author = {Heald, Adrian and Lllangasekera, Yasitha and Matheou, Andreas and Narayanan, Ram Prakash and White, Stephen and Habte-Asres, Hellena and Lay, Abigail and Shalamanova, Liliana and Ollier, William and Hitman, Graham A and Mallik, Ritwika and Kalra, Philip A and Whyte, Martin and Gibson, J Martin},
  title = {The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70318}
}
Kostenlos starten →